No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
WatchlistPaper Trade
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Junius Falcon : Buy when back to 720 or even 650. EPS up 70% YoY by 2025, will end up P/E 30+y, but only little growth in 2026, so it would go sideway in mid term.
LLY is diversified drugs, it is safer. NVO needs new drugs than weight loss. If they get out competed in that they are done. Its current EPS growth does support its current P/E